on Hardman & Co Research (isin : GB00BYYW9G87)
Hardman & Co: Shield Therapeutics' Focus on Cash Management
Shield Therapeutics, a commercial-stage pharmaceutical company, is focusing on delivering specialty products for unmet medical needs, primarily iron deficiency. Since launching in the US in July 2021, Shield and partner Viatris have increased physician awareness of Accrufer®, an oral iron deficiency drug. This effort is aimed at boosting prescriptions and generating sales momentum.
Positive trends in prescriptions recorded in 2022 and 2023 are anticipated to gain speed in 2024 and 2025. The company now aims to become cashflow positive by the second half of 2025. Enhanced financing options have also eliminated the need for a capital increase.
R. H.Copyright © 2024 FinanzWire, all reproduction and representation rights reserved. Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Hardman & Co Research news